Wildcat Capital Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Wildcat Capital Management’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-415,765	Closed	-$1.11M	–	39
2019 Q2	$1.11M	Hold	415,765	–	–	0.48%	23
2019 Q1	$1.98M	Hold	415,765	–	–	1.16%	15
2018 Q4	$998K	Hold	415,765	–	–	0.66%	14
2018 Q3	$1.83M	Hold	415,765	–	–	1.41%	11
2018 Q2	$2.99M	Hold	415,765	–	–	2.29%	10
2018 Q1	$2.14M	Sell	415,765 -1,322,467	-76%	-$9.41M	1.77%	12
2017 Q4	$6.61M	Sell	1,738,232 -1,061,558	-38%	-$2.76M	7.03%	4
2017 Q3	$4.76M	Hold	2,799,790	–	–	0.85%	9
2017 Q2	$5.6M	Hold	2,799,790	–	–	1.49%	8
2017 Q1	$11.1M	Hold	2,799,790	–	–	3.5%	5
2016 Q4	$13.7M	Hold	2,799,790	–	–	6.31%	4
2016 Q3	$21.7M	Hold	2,799,790	–	–	6.53%	4
2016 Q2	$15.7M	Buy	2,799,790 +176,257	+7%	+$1.13M	5.91%	4
2016 Q1	$14.1M	Hold	2,623,533	–	–	4.91%	5
2015 Q4	$22.9M	Buy	2,623,533 +912,470	+53%	+$7.7M	6.45%	4
2015 Q3	$14.4M	Buy	1,711,063 +975,051	+132%	+$15.5M	5.36%	4
2015 Q2	$13M	Buy	+736,012	New	+$9.46M	4.44%	5

Other funds holding SRNE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Wildcat Capital Management's SRNE Position: Q3 2019 in Review

Wildcat Capital Management sold out of Sorrento Therapeutics, Inc. (SRNE) in Q3 2019, closing a stake of 415,765 shares — an estimated $1.11M sold.

Wildcat Capital Management first reported a position in SRNE in Q2 2015 and held it in 17 quarters. The position peaked at $22.9M in Q4 2015. 85 funds tracked by Wall St. Rank hold SRNE as of Q3 2019.

Wildcat Capital Management reported no remaining Sorrento Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
Wildcat Capital Management sold 415,765 Sorrento Therapeutics, Inc. shares in Q3 2019, an estimated $1.11M.
Wildcat Capital Management first reported a position in Sorrento Therapeutics, Inc. in Q2 2015 and held it in 17 quarters.
Wildcat Capital Management's Sorrento Therapeutics, Inc. position peaked at $22.9M in Q4 2015.
85 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q3 2019.

Based on Wildcat Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.